Joelf Posted February 12 Share Posted February 12 TMB-003 Therapy to Reduce Scarring Wins FDA Orphan Drug Designation. Scleroderma treatment TMB-003 has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA). Scleroderma News, 01/14/2021. (Also see Clinical Trials) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles. Quote Link to post Share on other sites
Recommended Posts
Join the conversation
You can post now and register later. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.